Developer docs
API playgroundTry for free, no card

Search company profiles

Marine Biomedical

Full company profile

uuid004uiv4

Namestring
Marine Biomedical
Legal namestring
Marine Biomedical Pty Ltd
Company typeenum
Private
Founded yearint
2021
Short descriptiontext

Marine Biomedical is an Australian biotech developing PearlBone™, a nacre-derived bone graft substitute for orthopaedic, trauma, and reconstructive surgeons. The pre-revenue company operates from Broome, Western Australia, and is advancing through U.S. FDA 510(k) regulatory clearance.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersBroome, Australia
HQ citystring
Broome
HQ countrystring
Australia
HQ regionstring
Oceania
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
bone graft substitutes, orthopaedic medical devices, regenerative biomaterials, nacre-derived scaffolds, trauma surgery implants
Industry1 code
PRIMARYHLAHAEAG
Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
NAICS code1 code
  • Surgical Appliance and Supplies Manufacturing339113
SIC code1 code
  • Orthopedic, Prosthetic & Surgical Appliances & Supplies3842
Product category
Orthopaedic Medical Devices (Bone Graft Substitutes)
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1PearlBone™ Bone Graft Products
TypeOne Time License
Description

Marine Biomedical is pre-revenue with PearlBone™ currently undergoing regulatory review. Once FDA and TGA approvals are secured, the company will commercialize its nacre-derived bone graft substitute products for orthopaedic, trauma, and reconstructive surgery applications globally.

marinebiomedical.com.au
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1PearlBone™
Description

Marine-derived bone graft substitute product derived from nacre (mother of pearl) sourced from Western Australian pearl oysters. PearlBone™ is designed as a biocompatible scaffold to support natural bone regeneration in orthopaedic, trauma and reconstructive surgery applications. The lead product is PearlBone™ Putty.

marinebiomedical.com.au
Core offering1 text field

Marine Biomedical develops and manufactures PearlBone™, a marine-derived bone graft substitute produced from nacre (mother of pearl) harvested from sustainably sourced Western Australian pearl oyster shells. The lead formulation, PearlBone™ Putty, is engineered as a biocompatible, osteoconductive scaffold that fills bone voids and defects, supports new bone formation, and gradually integrates with the patient's native bone in orthopaedic, trauma, and reconstructive surgery applications. The product is manufactured at an in-house GMP cleanroom facility in Broome, Western Australia, and is currently progressing through FDA 510(k) review in the U.S. and TGA pathway in Australia.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Preclinical studies demonstrated PearlBone™ Putty was resorbed and replaced by new immature woven cancellous bone comparable to predicate device used extensively over past 20 years. No adverse tissue reactions in 3-month study period.
+1 more record
Product overview1 text field

Marine Biomedical operates a single-product portfolio centered on PearlBone™, a marine-derived bone graft substitute. The core product PearlBone™ is a biomaterial derived from nacre (mother of pearl) found in Western Australian pearl oyster shells. The lead commercial formulation is PearlBone™ Putty, designed for orthopaedic, trauma, and reconstructive surgery applications. Both products share the same nacre-derived base technology and are manufactured at the company's GMP facility in Broome, Western Australia.

Product and service2 records
1PearlBone™
CategoryBone Graft Substitute
Description

PearlBone™ is a marine-derived bone graft substitute developed from nacre (mother of pearl) sourced from sustainably certified Western Australian silver-lipped pearl oysters. It is engineered as a biocompatible, osteoconductive scaffold designed to fill bone voids and defects, support new bone formation, and integrate with the body's natural bone matrix in orthopaedic, trauma, and reconstructive surgery applications.

2PearlBone™ Putty
CategoryBone Graft Substitute
Description

PearlBone™ Putty is the lead commercial formulation of Marine Biomedical's nacre-derived bone graft substitute. It is a marine-derived calcium carbonate biomaterial developed from pearl oyster shell, engineered into a porous, biocompatible scaffold designed to fill bone voids and defects, support new bone formation, and integrate with the body's natural bone matrix. The material is gradually resorbed and replaced with new bone as part of the natural healing process.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
1Willie Creek Pearls
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-01-01
Description

Marine Biomedical was established through a partnership with Willie Creek Pearls, a renowned Broome pearling business. The partnership ensures a consistent supply of mother of pearl (nacre) from sustainably certified Western Australian silver-lipped pearl oysters for PearlBone™ manufacturing.

marinebiomedical.com.au
2University of Western Australia
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2016-01-01
Description

PearlBone™ was developed through research at UWA's Medical School. Professor Minghao Zheng (Winthrop Professor of Orthopaedic Research) is the inventor of PearlBone™ and a Marine Biomedical founding partner. Dr Rui Ruan co-invented the technology. Research expertise through UWA's Medical School continues to support product development.

marinebiomedical.com.au
Strategic tierMinorTypeStrategic or Co-development Partner
Description

MTPConnect WA Life Sciences Innovation Hub Director Kevin Pfleger expressed support for Marine Biomedical's potential to unlock marine-derived biomedical applications in Australia.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1SurGenTec
TypeEmerging player
Description

Emerging orthobiologics company developing bone graft and spine products for orthopaedic surgery. Comparable emerging player competing in the same bone void-filling niche with specialty surgeon-focused products.

TypeDirect peer
Description

Specialist bone graft substitute company commercializing CERAMENT, an injectable bone graft for orthopaedic trauma and infection. Closest direct competitor to PearlBone™, targeting the same surgical bone void-filling use cases with a comparable synthetic/biologic hybrid technology.

TypeEmerging player
Description

Regenerative medicine company commercializing cell-based therapies for inflammatory and orthopaedic conditions. Comparable as a specialty regenerative-medicine player pursuing regulatory approval in musculoskeletal indications, though at a later commercial stage.

TypeBroad incumbent
Description

Large US tissue bank supplying allograft-based bone graft substitutes and sports medicine tissues. Relevant incumbent competing on the allograft side of the same bone void-filling market Marine Biomedical is entering.

TypeBroad incumbent
Description

Global orthopaedic and sports medicine player with bone graft substitute and regenerative products. Comparable as a large incumbent in orthopaedic surgery distribution channels targeted by Marine Biomedical.

TypeBroad incumbent
Description

Major orthopaedic and trauma device company offering bone graft substitutes and surgical biologics alongside implants. Competes in the same surgical bone repair channels as PearlBone™, though as part of a much broader portfolio.

TypeDirect peer
Description

Australian regenerative medicine company developing orthopaedic biologic products. Direct commercial partner and strategic investor in Marine Biomedical, with overlapping focus on cartilage, tendon, and bone repair. Comparable in stage and therapeutic area, making it the closest functional peer.

TypeDirect peer
Description

Orthobiologics company focused on bone graft substitutes and spinal hardware for orthopaedic and trauma surgery. Direct competitor in the bone graft substitute category with comparable surgeon customer base.

TypeEmerging player
Description

Regenerative medicine company commercializing cellular and orthobiologic products for spine and orthopaedic applications. Comparable emerging peer with similar specialty orthobiologics positioning and surgeon-channel focus.

TypeBroad incumbent
Description

Global medical device leader with INFUSE Bone Graft and broader spinal/orthobiologics portfolio. Broad incumbent competing in the same bone graft substitute category and setting surgeon adoption standards.

Market position
Strengths1 record

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles14 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Marine Biomedical

Orthopaedic Medical Devices (Bone Graft Substitutes)marinebiomedical.com.au

Marine Biomedical is an Australian biotech developing PearlBone™, a nacre-derived bone graft substitute for orthopaedic, trauma, and reconstructive surgeons. The pre-revenue company operates from Broome, Western Australia, and is advancing through U.S. FDA 510(k) regulatory clearance.

Marine Biomedical firmographics

Firmographics
Name
Marine Biomedical
Legal name
Marine Biomedical Pty Ltd
Website
https://marinebiomedical.com.au
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
1–10 employees
Short description
Marine Biomedical is an Australian biotech developing PearlBone™, a nacre-derived bone graft substitute for orthopaedic, trauma, and reconstructive surgeons. The pre-revenue company operates from Broome, Western Australia, and is advancing through U.S. FDA 510(k) regulatory clearance.
Ownership category
akta.pro rank

Marine Biomedical industry classification

Industry
Product category
Orthopaedic Medical Devices (Bone Graft Substitutes)
NAICS
Surgical Appliance and Supplies Manufacturing (339113)
SIC
Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)
akta.pro industry
PRIMARYHLAHAEAG
Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)

Keywords

  • Bone graft substitutes
  • Orthopaedic medical devices
  • Regenerative biomaterials
  • Nacre-derived scaffolds
  • Trauma surgery implants

Where Marine Biomedical is headquartered

Location

Headquarters

HQ city
Broome
HQ country
Australia
HQ region
Oceania

Offices2 records

Markets served

Marine Biomedical business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

  1. PearlBone™ Bone Graft Products: Marine Biomedical is pre-revenue with PearlBone™ currently undergoing regulatory review. Once FDA and TGA approvals are secured, the company will commercialize its nacre-derived bone graft substitute products for orthopaedic, trauma, and reconstructive surgery applications globally.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Marine Biomedical product offering

Product offering

Core offering

Marine Biomedical develops and manufactures PearlBone™, a marine-derived bone graft substitute produced from nacre (mother of pearl) harvested from sustainably sourced Western Australian pearl oyster shells. The lead formulation, PearlBone™ Putty, is engineered as a biocompatible, osteoconductive scaffold that fills bone voids and defects, supports new bone formation, and gradually integrates with the patient's native bone in orthopaedic, trauma, and reconstructive surgery applications. The product is manufactured at an in-house GMP cleanroom facility in Broome, Western Australia, and is currently progressing through FDA 510(k) review in the U.S. and TGA pathway in Australia.

Product overview

Marine Biomedical operates a single-product portfolio centered on PearlBone™, a marine-derived bone graft substitute. The core product PearlBone™ is a biomaterial derived from nacre (mother of pearl) found in Western Australian pearl oyster shells. The lead commercial formulation is PearlBone™ Putty, designed for orthopaedic, trauma, and reconstructive surgery applications. Both products share the same nacre-derived base technology and are manufactured at the company's GMP facility in Broome, Western Australia.

Differentiator

Problem solved

Functional benefit

Brands

  • PearlBone™: Marine-derived bone graft substitute product derived from nacre (mother of pearl) sourced from Western Australian pearl oysters. PearlBone™ is designed as a biocompatible scaffold to support natural bone regeneration in orthopaedic, trauma and reconstructive surgery applications. The lead product is PearlBone™ Putty.

Products and services

  • PearlBone™ PearlBone™ is a marine-derived bone graft substitute developed from nacre (mother of pearl) sourced from sustainably certified Western Australian silver-lipped pearl oysters. It is engineered as a biocompatible, osteoconductive scaffold designed to fill bone voids and defects, support new bone formation, and integrate with the body's natural bone matrix in orthopaedic, trauma, and reconstructive surgery applications.
  • PearlBone™ Putty PearlBone™ Putty is the lead commercial formulation of Marine Biomedical's nacre-derived bone graft substitute. It is a marine-derived calcium carbonate biomaterial developed from pearl oyster shell, engineered into a porous, biocompatible scaffold designed to fill bone voids and defects, support new bone formation, and integrate with the body's natural bone matrix. The material is gradually resorbed and replaced with new bone as part of the natural healing process.

Quantifiable outcome

  • Preclinical studies demonstrated PearlBone™ Putty was resorbed and replaced by new immature woven cancellous bone comparable to predicate device used extensively over past 20 years. No adverse tissue reactions in 3-month study period.
  • +1 more outcomes

Companies that use Marine Biomedical

Customer profile

Segments3 records

Ideal customer profiles1 record

Marine Biomedical technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Marine Biomedical partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core and minor.

  • Willie Creek PearlscoreStrategic or Co-development Partner · 1 January 2021Marine Biomedical was established through a partnership with Willie Creek Pearls, a renowned Broome pearling business. The partnership ensures a consistent supply of mother of pearl (nacre) from sustainably certified Western Australian silver-lipped pearl oysters for PearlBone™ manufacturing.
  • University of Western AustraliacoreStrategic or Co-development Partner · 1 January 2016PearlBone™ was developed through research at UWA's Medical School. Professor Minghao Zheng (Winthrop Professor of Orthopaedic Research) is the inventor of PearlBone™ and a Marine Biomedical founding partner. Dr Rui Ruan co-invented the technology. Research expertise through UWA's Medical School continues to support product development.
  • MTPConnect WA Life Sciences Innovation HubminorStrategic or Co-development PartnerMTPConnect WA Life Sciences Innovation Hub Director Kevin Pfleger expressed support for Marine Biomedical's potential to unlock marine-derived biomedical applications in Australia.

Scale indicators4 records

Recent moves8 records

Expansion highlights6 records

Marine Biomedical competitors and assessment

Company assessment

Emerging players

  • SurGenTec: Emerging orthobiologics company developing bone graft and spine products for orthopaedic surgery. Comparable emerging player competing in the same bone void-filling niche with specialty surgeon-focused products.
  • Mesoblast: Regenerative medicine company commercializing cell-based therapies for inflammatory and orthopaedic conditions. Comparable as a specialty regenerative-medicine player pursuing regulatory approval in musculoskeletal indications, though at a later commercial stage.
  • Celling Biosciences: Regenerative medicine company commercializing cellular and orthobiologic products for spine and orthopaedic applications. Comparable emerging peer with similar specialty orthobiologics positioning and surgeon-channel focus.

Direct peers

  • BoneSupport: Specialist bone graft substitute company commercializing CERAMENT, an injectable bone graft for orthopaedic trauma and infection. Closest direct competitor to PearlBone™, targeting the same surgical bone void-filling use cases with a comparable synthetic/biologic hybrid technology.
  • Orthocell: Australian regenerative medicine company developing orthopaedic biologic products. Direct commercial partner and strategic investor in Marine Biomedical, with overlapping focus on cartilage, tendon, and bone repair. Comparable in stage and therapeutic area, making it the closest functional peer.
  • Xtant Medical: Orthobiologics company focused on bone graft substitutes and spinal hardware for orthopaedic and trauma surgery. Direct competitor in the bone graft substitute category with comparable surgeon customer base.

Broad incumbents

  • MTF Biologics: Large US tissue bank supplying allograft-based bone graft substitutes and sports medicine tissues. Relevant incumbent competing on the allograft side of the same bone void-filling market Marine Biomedical is entering.
  • Smith & Nephew: Global orthopaedic and sports medicine player with bone graft substitute and regenerative products. Comparable as a large incumbent in orthopaedic surgery distribution channels targeted by Marine Biomedical.
  • Stryker: Major orthopaedic and trauma device company offering bone graft substitutes and surgical biologics alongside implants. Competes in the same surgical bone repair channels as PearlBone™, though as part of a much broader portfolio.
  • Medtronic (Spinal & Biologics): Global medical device leader with INFUSE Bone Graft and broader spinal/orthobiologics portfolio. Broad incumbent competing in the same bone graft substitute category and setting surgeon adoption standards.

Market position

Strengths1 record

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Marine Biomedical social profiles

Digital presence

Marine Biomedical compliance and trust

Trust signal

Compliance2 records

Marine Biomedical financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Marine Biomedical leadership team

Management profile

Number of profiles

Profiles14 records

Marine Biomedical funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Marine Biomedical M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Marine Biomedical

What does Marine Biomedical do?

Marine Biomedical develops and manufactures PearlBone™, a marine-derived bone graft substitute produced from nacre (mother of pearl) harvested from sustainably sourced Western Australian pearl oyster shells. The lead formulation, PearlBone™ Putty, is engineered as a biocompatible, osteoconductive scaffold that fills bone voids and defects, supports new bone formation, and gradually integrates with the patient's native bone in orthopaedic, trauma, and reconstructive surgery applications. The product is manufactured at an in-house GMP cleanroom facility in Broome, Western Australia, and is currently progressing through FDA 510(k) review in the U.S. and TGA pathway in Australia.

Is Marine Biomedical a public or private company?

Marine Biomedical is a private company. It is classified as venture growth investor backed and is currently operating.

When was Marine Biomedical founded?

Marine Biomedical was founded in 2021. It employs 1 to 10 people.

Where is Marine Biomedical based?

Marine Biomedical is headquartered in Broome, Australia, in the Oceania region.

How does Marine Biomedical make money?

One revenue line is on record: pearlBone™ Bone Graft Products.

Who are Marine Biomedical's main competitors?

Emerging players on record are SurGenTec, Mesoblast and Celling Biosciences. Direct peers are BoneSupport, Orthocell and Xtant Medical. Broad incumbents are MTF Biologics, Smith & Nephew, Stryker and Medtronic (Spinal & Biologics).

Does Marine Biomedical have an API?

No public API is recorded for Marine Biomedical.

What industry is Marine Biomedical in?

Marine Biomedical's product category is Orthopaedic Medical Devices (Bone Graft Substitutes). Its primary akta.pro industry code is HLAHAEAG, Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM). Its NAICS code is 339113 and its SIC code is 3842.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
YahooFDA Approves First-of-Its-Kind Bone Repair Material Made From Pearl ShellsThe FDA granted 510(k) clearance to PearlBone Putty 1600, a bone repair material made from pearl shells. The material converts nacre into calcium phosphate in 24 hours, offering a sustainable alternative to traditional grafts. Marine Biomedical must still partner with US manufacturers for commercial availability.ABCPearlBone from WA wins FDA approval for US orthopaedic marketMarine Biomedical received FDA clearance for PearlBone, a bone graft substitute made from mother-of-pearl harvested in Western Australia. The product is the first of its kind from nacre and is intended for US bone fracture repair. The company plans to expand into dental treatments and potentially involve the broader pearling industry.Mirage NewsFDA Clears PearlBone for Bone Fracture RepairThe FDA granted 510(k) clearance to PearlBone putty, a nacre-derived bone graft substitute developed by Marine Biomedical Ltd. The product, made from sustainably sourced Western Australian pearl shell, is the first of its kind for bone fracture repair. The company plans to use the clearance to enter the US orthopaedic market.ABCKimberley mother-of-pearl could become synthetic bone in world-first medical collaborationUWA and Marine Biomedical are developing PearlBone, a synthetic bone substitute from mother-of-pearl, for bone grafting and reconstructive surgery. The collaboration aims to diversify the Kimberley pearling industry, with regulatory approval targeted within three to four years. Future applications may include dental fillings and spinal surgery.